 The present study evaluated the efficacy of quadrivalent human papillomavirus, HPV, vaccine, in treating multiple warts, finding that 46.67% of patients showed complete response, 16.67% partial response, and 36.67% no response. No severe adverse events were noted, making the HPV vaccine a convenient and less painful alternative to conventional destructive methods for incompetent cases such as those with multiple warts, dangerous lesion locations, or uncooperative patients.